Hudson Valley Investment Advisors Inc. ADV Has $37.23 Million Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Hudson Valley Investment Advisors Inc. ADV lessened its stake in Eli Lilly and Company (NYSE:LLY) by 0.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 48,231 shares of the company’s stock after selling 85 shares during the quarter. Eli Lilly and Company makes up about 4.2% of Hudson Valley Investment Advisors Inc. ADV’s holdings, making the stock its 3rd largest position. Hudson Valley Investment Advisors Inc. ADV’s holdings in Eli Lilly and Company were worth $37,234,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Legacy Private Trust Co. grew its holdings in shares of Eli Lilly and Company by 10.4% in the fourth quarter. Legacy Private Trust Co. now owns 9,616 shares of the company’s stock valued at $7,424,000 after acquiring an additional 904 shares in the last quarter. Douglas Lane & Associates LLC raised its position in shares of Eli Lilly and Company by 10.9% in the fourth quarter. Douglas Lane & Associates LLC now owns 2,823 shares of the company’s stock valued at $2,179,000 after purchasing an additional 278 shares during the period. InvesTrust purchased a new stake in shares of Eli Lilly and Company during the fourth quarter worth $8,797,000. Private Client Services LLC lifted its holdings in Eli Lilly and Company by 8.9% during the 4th quarter. Private Client Services LLC now owns 1,172 shares of the company’s stock worth $905,000 after purchasing an additional 96 shares in the last quarter. Finally, Fulton Bank N.A. boosted its position in shares of Eli Lilly and Company by 9.5% in the fourth quarter. Fulton Bank N.A. now owns 14,758 shares of the company’s stock valued at $11,393,000 after acquiring an additional 1,282 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on LLY shares. Redburn Atlantic upgraded Eli Lilly and Company to a “hold” rating in a research report on Monday, November 4th. Wolfe Research assumed coverage on shares of Eli Lilly and Company in a research note on Friday, November 15th. They issued an “outperform” rating and a $1,000.00 target price on the stock. Barclays lowered their price objective on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating on the stock in a research report on Thursday, October 31st. Deutsche Bank Aktiengesellschaft reduced their target price on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating on the stock in a research note on Monday, November 4th. Finally, Truist Financial increased their price objective on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a research report on Thursday, October 10th. Four investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $1,002.22.

Eli Lilly and Company Trading Up 1.7 %

LLY opened at $786.15 on Friday. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. Eli Lilly and Company has a 52 week low of $612.70 and a 52 week high of $972.53. The stock has a market cap of $746.30 billion, a PE ratio of 84.99, a PEG ratio of 2.99 and a beta of 0.41. The business has a 50 day moving average of $786.48 and a 200-day moving average of $860.65.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing the consensus estimate of $1.52 by ($0.34). The firm had revenue of $11.44 billion for the quarter, compared to analysts’ expectations of $12.09 billion. Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The business’s quarterly revenue was up 20.4% compared to the same quarter last year. During the same period in the prior year, the business posted $0.10 EPS. Equities research analysts predict that Eli Lilly and Company will post 13.18 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 14th will be given a $1.50 dividend. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.30. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.76%. The ex-dividend date is Friday, February 14th. Eli Lilly and Company’s payout ratio is currently 64.86%.

Eli Lilly and Company declared that its Board of Directors has authorized a share buyback plan on Monday, December 9th that authorizes the company to buyback $15.00 billion in outstanding shares. This buyback authorization authorizes the company to buy up to 2% of its stock through open market purchases. Stock buyback plans are usually an indication that the company’s leadership believes its shares are undervalued.

Insider Buying and Selling

In related news, CAO Donald A. Zakrowski sold 900 shares of the firm’s stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $803.38, for a total transaction of $723,042.00. Following the completion of the sale, the chief accounting officer now owns 5,480 shares of the company’s stock, valued at $4,402,522.40. This trade represents a 14.11 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.